LENZ Therapeutics, Inc. (LENZ)Healthcare | Biotechnology | Solana Beach, United States | NasdaqGS
5.23 USD
-0.36
(-6.440%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 5.31 +0.08 (1.530%) ⇧ (July 13, 2026, 7:39 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 3:40 a.m. EDT
LENZ Therapeutics presents a classic value trap scenario where the balance sheet looks pristine on paper but the business reality is deteriorating. While the company holds a fortress-like cash position relative to its debt, the fundamentals tell a grim story: negative operating cash flow, negative free cash flow, and a trailing P/E that is mathematically impossible due to losses. The stock has already corrected massively from its highs, yet the recent price action shows no sign of stabilization, trading well below both its 50-day and 200-day averages. The lack of revenue growth and the heavy reliance on dilutive financing to stay alive suggest the core business model is struggling to gain traction. Furthermore, the recent news cycle highlights corporate highlights like home delivery expansions, which are standard operational updates rather than transformative breakthroughs that would justify a premium valuation. With analysts maintaining a 'strong buy' rating based on potential future upside that seems disconnected from current execution risks, the disconnect between the optimistic analyst consensus and the harsh financial reality creates significant danger for investors. The options market agrees with the pessimism, with traders buying insurance against further drops rather than betting on a rebound. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.165164 |
| MSTL | 0.264164 |
| AutoARIMA | 0.265372 |
| AutoETS | 0.270302 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 3.93 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.268 |
| Excess Kurtosis | -0.31 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Last Dividend Date | 2024-03-21 |
| Debt to Equity Ratio | 0.273 |
| Revenue per Share | 0.705 |
| Market Cap | 163,983,488 |
| Forward P/E | -1.51 |
| Beta | 1.62 |
| Website | https://www.lenz-tx.com |
As of July 11, 2026, 3:40 a.m. EDT: Speculators are positioning heavily for downside protection with massive open interest in out-of-the-money puts (strikes 10, 12.5, 15) and significant new volume flowing into deep OTM puts for late 2027. Conversely, call activity is sparse and concentrated near the money, with very little speculative capital betting on a recovery despite the low implied volatility suggesting complacency. The skew indicates a market expecting continued stagnation or further decline rather than a catalyst-driven rally.
| Date | Dividend | Yield % |
|---|---|---|
| 2024-03-22 | 7.21 | 44.506171 |
| 2024-03-15 | 7.21 | 30.838324 |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.83427215 |
| Address1 | 201 Lomas Santa Fe Drive |
| Address2 | Suite 300 |
| All Time High | 238.0 |
| All Time Low | 5.23 |
| Ask | 6.66 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,088,110 |
| Average Daily Volume3 Month | 840,872 |
| Average Volume | 840,872 |
| Average Volume10Days | 1,088,110 |
| Beta | 1.621 |
| Bid | 3.96 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 7.861 |
| City | Solana Beach |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.23 |
| Current Ratio | 10.399 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 5.58 |
| Day Low | 5.2 |
| Debt To Equity | 0.273 |
| Display Name | LENZ Therapeutics |
| Dividend Date | 1,710,979,200 |
| Earnings Call Timestamp End | 1,778,531,400 |
| Earnings Call Timestamp Start | 1,778,531,400 |
| Earnings Timestamp | 1,778,529,600 |
| Earnings Timestamp End | 1,785,355,200 |
| Earnings Timestamp Start | 1,785,355,200 |
| Ebitda | -117,980,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.794 |
| Enterprise To Revenue | -4.466 |
| Enterprise Value | -93,728,520 |
| Eps Current Year | -4.56382 |
| Eps Forward | -3.46847 |
| Eps Trailing Twelve Months | -3.64 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.1554 |
| Fifty Day Average Change | -1.9253998 |
| Fifty Day Average Change Percent | -0.26908347 |
| Fifty Two Week Change Percent | -83.427216 |
| Fifty Two Week High | 50.4 |
| Fifty Two Week High Change | -45.170002 |
| Fifty Two Week High Change Percent | -0.89623016 |
| Fifty Two Week Low | 5.2 |
| Fifty Two Week Low Change | 0.03000021 |
| Fifty Two Week Low Change Percent | 0.0057692714 |
| Fifty Two Week Range | 5.2 - 50.4 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,624,627,800,000 |
| Float Shares | 18,481,220 |
| Forward Eps | -3.46847 |
| Forward P E | -1.5078695 |
| Free Cashflow | -48,814,752 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 152 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.92882 |
| Gross Profits | 19,495,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02654 |
| Held Percent Institutions | 1.09982 |
| Implied Shares Outstanding | 31,354,394 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Dividend Date | 1,711,065,600 |
| Last Dividend Value | 7.21 |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,711,065,600 |
| Last Split Factor | 1:7 |
| Long Business Summary | LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California. |
| Long Name | LENZ Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 163,983,488 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_370131860 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -108,996,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 175,271,062 |
| Number Of Analyst Opinions | 7 |
| Open | 5.54 |
| Operating Cashflow | -86,703,000 |
| Operating Margins | -23.21673 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 858 925 7000 |
| Post Market Change | 0.07999992 |
| Post Market Change Percent | 1.5296352 |
| Post Market Price | 5.31 |
| Post Market Time | 1,783,985,985 |
| Previous Close | 5.59 |
| Price Eps Current Year | -1.1459699 |
| Price Hint | 2 |
| Price To Book | 0.6653097 |
| Price To Sales Trailing12 Months | 7.81283 |
| Profit Margins | 0.0 |
| Quick Ratio | 10.107 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.28571 |
| Region | US |
| Regular Market Change | -0.36 |
| Regular Market Change Percent | -6.44007 |
| Regular Market Day High | 5.58 |
| Regular Market Day Low | 5.2 |
| Regular Market Day Range | 5.2 - 5.58 |
| Regular Market Open | 5.54 |
| Regular Market Previous Close | 5.59 |
| Regular Market Price | 5.23 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,493,448 |
| Return On Assets | -0.31222 |
| Return On Equity | -0.49713 |
| Revenue Per Share | 0.705 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 31,354,394 |
| Shares Percent Shares Out | 0.3327 |
| Shares Short | 10,433,083 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 10,231,978 |
| Short Name | LENZ Therapeutics, Inc. |
| Short Percent Of Float | 0.5481 |
| Short Ratio | 14.3 |
| Source Interval | 15 |
| State | CA |
| Symbol | LENZ |
| Target High Price | 60.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 32.0 |
| Target Median Price | 31.0 |
| Total Cash | 258,384,992 |
| Total Cash Per Share | 8.241 |
| Total Debt | 673,000 |
| Total Revenue | 20,989,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.64 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 17.58955 |
| Two Hundred Day Average Change | -12.35955 |
| Two Hundred Day Average Change Percent | -0.7026644 |
| Type Disp | Equity |
| Volume | 1,493,448 |
| Website | https://www.lenz-tx.com |
| Zip | 92,075 |